Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Globeflex Capital L P

Globeflex Capital L P raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 59.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,073 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,000 shares during the quarter. Globeflex Capital L P’s holdings in Jazz Pharmaceuticals were worth $994,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Pacer Advisors Inc. boosted its holdings in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares in the last quarter. Cinctive Capital Management LP purchased a new position in Jazz Pharmaceuticals during the third quarter valued at $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after buying an additional 100,112 shares during the last quarter. GW&K Investment Management LLC raised its position in shares of Jazz Pharmaceuticals by 26.6% in the fourth quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock valued at $57,142,000 after buying an additional 97,589 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Jazz Pharmaceuticals by 501.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock valued at $13,800,000 after buying an additional 93,422 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the sale, the chief accounting officer now owns 7,012 shares of the company’s stock, valued at $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the sale, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,736 shares of company stock worth $4,022,825. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Trading Up 1.4 %

NASDAQ JAZZ opened at $137.96 on Friday. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06. The company’s 50 day moving average price is $129.52 and its 200 day moving average price is $120.76. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market capitalization of $8.38 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 1.04 and a beta of 0.44.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on JAZZ shares. JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Piper Sandler reissued an “overweight” rating and issued a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Barclays reissued an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Finally, Robert W. Baird raised their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $190.53.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.